ATE355279T1 - Pyrazole als modulatoren des östrogenrezeptors - Google Patents
Pyrazole als modulatoren des östrogenrezeptorsInfo
- Publication number
- ATE355279T1 ATE355279T1 AT99940917T AT99940917T ATE355279T1 AT E355279 T1 ATE355279 T1 AT E355279T1 AT 99940917 T AT99940917 T AT 99940917T AT 99940917 T AT99940917 T AT 99940917T AT E355279 T1 ATE355279 T1 AT E355279T1
- Authority
- AT
- Austria
- Prior art keywords
- estrogen receptor
- pyrazoles
- modulators
- compounds
- modulating
- Prior art date
Links
- 102000015694 estrogen receptors Human genes 0.000 title abstract 4
- 108010038795 estrogen receptors Proteins 0.000 title abstract 4
- 150000003217 pyrazoles Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Developing Agents For Electrophotography (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9577298P | 1998-08-07 | 1998-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE355279T1 true ATE355279T1 (de) | 2006-03-15 |
Family
ID=22253525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99940917T ATE355279T1 (de) | 1998-08-07 | 1999-08-06 | Pyrazole als modulatoren des östrogenrezeptors |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US6291505B1 (de) |
| EP (1) | EP1102753B1 (de) |
| JP (1) | JP2002522422A (de) |
| AT (1) | ATE355279T1 (de) |
| AU (1) | AU5467799A (de) |
| DE (1) | DE69935335T2 (de) |
| ES (1) | ES2281186T3 (de) |
| WO (1) | WO2000007996A2 (de) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000009500A2 (en) * | 1998-08-11 | 2000-02-24 | Nihon Bayer Agrochem K.K. | Nematicidal pyrazoles |
| US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
| GB0016787D0 (en) | 2000-07-07 | 2000-08-30 | Pfizer Ltd | Compounds useful in therapy |
| US6878729B2 (en) * | 2001-05-04 | 2005-04-12 | The Procter & Gamble Company | Medicinal uses of dihydropyrazoles |
| CN1289075C (zh) * | 2001-07-09 | 2006-12-13 | 佐纳根有限公司 | 富含反式克罗米酚的克罗米酚组合物的用途 |
| US7737185B2 (en) * | 2001-07-09 | 2010-06-15 | Repros Therapeutics Inc. | Methods and compositions with trans-clomiphene |
| US20040010027A1 (en) * | 2001-12-17 | 2004-01-15 | Pharmacia & Upjohn Spa | Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them |
| JP4399265B2 (ja) | 2001-12-21 | 2010-01-13 | ヴァーナリス（ケンブリッジ）リミテッド | ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用 |
| US7282512B2 (en) * | 2002-01-17 | 2007-10-16 | Smithkline Beecham Corporation | Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors |
| AU2003234567A1 (en) | 2002-05-15 | 2003-12-02 | Janssen Pharmaceutica N.V. | N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors |
| EP1398029A1 (de) * | 2002-09-10 | 2004-03-17 | LION Bioscience AG | 3-substituierte Pyrazol-Derivate,die an den NR3B1 Rezeptor binden |
| GB0228417D0 (en) * | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
| WO2004078261A1 (en) * | 2003-03-07 | 2004-09-16 | The University Court Of The University Of Aberdeen | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
| EP1601657A1 (de) * | 2003-03-12 | 2005-12-07 | Vertex Pharmaceuticals Incorporated | Pyrazol-modulatoren von atp-bindende-cassette transportern |
| US7205329B2 (en) * | 2003-05-30 | 2007-04-17 | Microbia, Inc. | Modulators of CRTH2 activity |
| US20070161698A1 (en) * | 2003-05-30 | 2007-07-12 | Microbia, Inc. | Modulators of CRTH2 Activity |
| US7465739B2 (en) | 2003-06-10 | 2008-12-16 | Solvay Pharmaceuticals B.V. | Compounds and their use in therapy |
| JP2007527397A (ja) * | 2003-07-01 | 2007-09-27 | マイクロバイア インコーポレイテッド | Ｃｏｘ−２及びｆａａｈ阻害剤 |
| US20070293542A1 (en) * | 2003-10-16 | 2007-12-20 | Cali Brian M | Selective Cox-2 Inhibitors |
| US8088758B2 (en) | 2003-11-12 | 2012-01-03 | Abbott Products Gmbh | 17β-hydroxysteroid dehydrogenase type I inhibitors |
| EP2228369A1 (de) | 2003-12-23 | 2010-09-15 | Astex Therapeutics Ltd. | Pyrazolderivate als modulatoren von proteinkinase |
| US20050234030A1 (en) * | 2004-04-20 | 2005-10-20 | Wilmin Bartolini | Modulators of CRTH2, COX-2 and FAAH |
| US20050234244A1 (en) * | 2004-04-20 | 2005-10-20 | Wilmin Bartolini | Synthesis of COX-2 and FAAH inhibitors |
| EP1776098A1 (de) * | 2004-07-14 | 2007-04-25 | Repros Therapeutics Inc. | Trans-clomiphen zur behandlung von benigner prostatahypertrophie; prostatakrebs; hypogonadismus; erhöhten triglyceriden und erhöhten cholesterinwerten |
| WO2006033943A2 (en) | 2004-09-17 | 2006-03-30 | Exelixis, Inc | Pyrazole kinase modulators and methods of use |
| WO2006042172A2 (en) * | 2004-10-09 | 2006-04-20 | The Regents Of The University Of Michigan | Gender differences in experimental aortic aneurysm formation |
| PE20060949A1 (es) * | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
| WO2006084153A2 (en) * | 2005-02-04 | 2006-08-10 | Repros Therapeutics Inc. | Methods and materials with trans-clomiphene for the treatment of male infertility |
| NZ560551A (en) * | 2005-03-22 | 2010-02-26 | Repros Therapeutics Inc | Dosing regimes for trans-clomiphene |
| TW200720254A (en) * | 2005-04-07 | 2007-06-01 | Nippon Kayaku Kk | Use of 3,5-diphenyl pyrazole derivatives as anti-tumor agent |
| US7456188B1 (en) | 2005-04-28 | 2008-11-25 | Bristol-Myers Squibb Company | C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators |
| US8030298B2 (en) | 2005-05-26 | 2011-10-04 | Abbott Products Gmbh | 17β-HSD1 and STS inhibitors |
| US8343953B2 (en) | 2005-06-22 | 2013-01-01 | Astex Therapeutics Limited | Pharmaceutical compounds |
| WO2006136837A2 (en) * | 2005-06-23 | 2006-12-28 | Astex Therapeutics Limited | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators |
| EP2051977A2 (de) * | 2006-07-20 | 2009-04-29 | Amgen Inc. | SUBSTITUIERTE AROMATISCHE AZOL-HETEROCYCLEN ALS LLbeta-HSD-1-HEMMER |
| US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
| US20080096950A1 (en) * | 2006-10-19 | 2008-04-24 | Karl Richard Gibson | Compounds Useful In Therapy |
| US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| GB0702862D0 (en) * | 2007-02-14 | 2007-03-28 | Univ Aberdeen | Therapeutic compounds |
| GB0704932D0 (en) | 2007-03-14 | 2007-04-25 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| MX2010004195A (es) | 2007-10-16 | 2010-06-02 | Repros Therapeutics Inc | Trans-clomifeno para el sindrome metabolico. |
| KR20100122513A (ko) | 2008-07-17 | 2010-11-22 | 아사히 가세이 파마 가부시키가이샤 | 질소 함유 복소환 화합물 |
| US8653098B2 (en) | 2008-11-20 | 2014-02-18 | Genentech, Inc. | Pyrazolopyridine PI3K inhibitor compounds and methods of use |
| AR078538A1 (es) | 2009-10-07 | 2011-11-16 | Karobio Ab | Pirroles e imidazoles sustituidos como ligandos del receptor de estrogenos |
| BR112012024346A2 (pt) | 2010-04-28 | 2016-05-24 | Toray Industries | agente terapêutico ou agente profilático para a doença de alzheimer |
| UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування | |
| GB201113538D0 (en) | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
| US9475816B2 (en) | 2012-09-07 | 2016-10-25 | Takeda Pharmaceutical Company Limited | Substituted-1,4-dihydropyrazolo[4,3-b]indoles |
| CN104994877A (zh) | 2012-11-02 | 2015-10-21 | 利普生物药剂公司 | 用于癌症治疗的反式-克罗米芬 |
| AU2014300894A1 (en) | 2013-06-25 | 2016-01-28 | Forendo Pharma Ltd | Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase |
| JP6456373B2 (ja) | 2013-06-25 | 2019-01-23 | フォレンド ファーマ リミテッド | １７β−ヒドロキシステロイドデヒドロゲナーゼ タイプ１の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体 |
| TW201512215A (zh) | 2013-06-25 | 2015-04-01 | Forendo Pharma Ltd | 治療活性雌三烯噻唑衍生物 |
| CN104016921A (zh) * | 2014-03-24 | 2014-09-03 | 南开大学 | 具有抗肝癌活性的1-取代苯基-4-多取代苯基-5-甲硫基-1h吡唑类化合物 |
| WO2016102775A1 (en) | 2014-12-23 | 2016-06-30 | Forendo Pharma Ltd | PRODRUGS OF 17β-HSD1 -INHIBITORS |
| US10413557B2 (en) | 2014-12-23 | 2019-09-17 | Forendo Pharma Ltd. | Prodrugs of 17.BETA.-HSD1-inhibitors |
| WO2016202935A1 (en) | 2015-06-19 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
| CN105523955B (zh) * | 2015-12-14 | 2018-08-17 | 北京嘉林药业股份有限公司 | 化合物及其在制备药物中的用途 |
| GB201706806D0 (en) * | 2017-04-28 | 2017-06-14 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| JP2021518855A (ja) * | 2018-03-02 | 2021-08-05 | ユニヴェルシテ ド ローザンヌ | Ｗｎｔシグナル伝達経路阻害剤としてのピラゾール誘導体 |
| WO2025096683A1 (en) * | 2023-10-30 | 2025-05-08 | University Of Health Sciences And Pharmacy In St. Louis | Err modulators |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4146721A (en) * | 1969-09-12 | 1979-03-27 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pyrazol-4-acetic acid compounds |
| FR2104932A1 (en) * | 1970-09-08 | 1972-04-28 | Ferlux | O-hydroxyphenyl pyrazoles - hypocholesterolemics anti inflammatories analgesics etc |
| ZA744908B (en) * | 1973-09-17 | 1975-08-27 | American Cyanamid Co | Catalytic dehydrogenation process for the preparation of 3,5-disubstituted pyrazoles |
| US4112108A (en) | 1976-12-06 | 1978-09-05 | Sandoz, Inc. | Isoxazolyl benzamides |
| US4229204A (en) | 1978-12-04 | 1980-10-21 | Monsanto Company | Trifluoromethylphenyl isoxazolyl benzoates |
| CA1128526A (en) | 1979-10-05 | 1982-07-27 | Cdc Life Sciences Inc. | 3,4-diarylisoxazol-5-acetic acids |
| DE3119727A1 (de) | 1981-05-18 | 1982-12-02 | Sterling Drug Inc., 10019 New York, N.Y. | "4-(arylaliphatische)-isoxazole, welche als antivirale mittel nuetzlich sind, und deren herstellung" |
| CA2036192A1 (en) | 1990-02-13 | 1991-08-14 | Nicholas Meanwell | Heterocyclic carboxylic acids and esters |
| DE4126543A1 (de) * | 1991-08-10 | 1993-02-11 | Chem & Pharm Patent Hold Ltd | 3(5)-(hydroxyaryl)-pyrazole und ihre verwendung als wirkstoffe in arzneimittel |
| DE4230839A1 (de) * | 1991-09-18 | 1993-03-25 | Ciba Geigy Ag | Polyarylenether mit pyrazoleinheiten |
| JPH06135948A (ja) | 1992-10-30 | 1994-05-17 | Taiho Yakuhin Kogyo Kk | スチレン誘導体又はその塩 |
| DE4408084A1 (de) | 1994-03-10 | 1995-09-14 | Hoechst Ag | 3,5-Disubstituierte und 3,4,5-trisubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| JP3267300B2 (ja) | 1995-02-13 | 2002-03-18 | ジー．ディー．サール アンド カンパニー | 炎症の治療のための置換イソオキサゾール |
| WO1997001551A1 (en) | 1995-06-26 | 1997-01-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazole compounds and pharmaceutical compositions |
| AU5041400A (en) | 1999-05-24 | 2000-12-12 | America River Nutrition, Inc. | Tocotrienols and geranylgeraniol from LTiGTbixa orellanaLT/iGT byproducts |
| CN1281604C (zh) | 1999-06-03 | 2006-10-25 | 帝国脏器制药株式会社 | 取代吡唑化合物 |
-
1999
- 1999-08-06 DE DE69935335T patent/DE69935335T2/de not_active Expired - Lifetime
- 1999-08-06 AT AT99940917T patent/ATE355279T1/de not_active IP Right Cessation
- 1999-08-06 EP EP99940917A patent/EP1102753B1/de not_active Expired - Lifetime
- 1999-08-06 WO PCT/US1999/017799 patent/WO2000007996A2/en not_active Ceased
- 1999-08-06 AU AU54677/99A patent/AU5467799A/en not_active Abandoned
- 1999-08-06 ES ES99940917T patent/ES2281186T3/es not_active Expired - Lifetime
- 1999-08-06 JP JP2000563630A patent/JP2002522422A/ja not_active Ceased
- 1999-08-06 US US09/369,747 patent/US6291505B1/en not_active Ceased
-
2001
- 2001-09-18 US US09/954,039 patent/US6727273B2/en not_active Expired - Fee Related
-
2003
- 2003-06-12 US US10/461,914 patent/US20040077701A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000007996A3 (en) | 2000-08-31 |
| ES2281186T3 (es) | 2007-09-16 |
| WO2000007996A8 (en) | 2000-10-19 |
| EP1102753B1 (de) | 2007-02-28 |
| EP1102753A2 (de) | 2001-05-30 |
| WO2000007996A2 (en) | 2000-02-17 |
| US20040034081A9 (en) | 2004-02-19 |
| JP2002522422A (ja) | 2002-07-23 |
| US20040077701A1 (en) | 2004-04-22 |
| US6291505B1 (en) | 2001-09-18 |
| US20020111374A1 (en) | 2002-08-15 |
| AU5467799A (en) | 2000-02-28 |
| DE69935335D1 (de) | 2007-04-12 |
| US6727273B2 (en) | 2004-04-27 |
| DE69935335T2 (de) | 2007-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69935335D1 (de) | Pyrazole als modulatoren des östrogenrezeptors | |
| ATE315033T1 (de) | Subtituierte isoxazole derivate als estrogen rezeptor modulatore | |
| YU596A (sh) | Estrogen agonisti/antagonisti | |
| YU18400A (sh) | Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja | |
| ATE259215T1 (de) | Zusammensetzung zur regulierung des hauterscheinungsbildes | |
| MX338710B (es) | Compuestos biciclicos moduladores de receptor de androgeno y progesterona, y metodos. | |
| SI1054887T1 (sl) | Biciklicni pridinski in primidinski derivati kot receptorski antagonisti nevropeptida y | |
| MX9805253A (es) | Antagonistas del receptor de vitronectina. | |
| YU7797A (sh) | Kombinovana terapija za osteoporozu | |
| BG104247A (bg) | Производни на резорцинола | |
| MY121047A (en) | Bicyclo [2.2.1] heptanes and related compounds | |
| BR9710255A (pt) | Método para o tratamento de cáncer composto de retinóide de adamantila composição farmacéutica ou cosmética de matéria método de tratamento ou de prevenção e método para controlar | |
| AU9102198A (en) | Indole-3-carbinol, diindolylmethane and substituted analogs as antiestrogens | |
| EP0720635A4 (de) | Phthalocyaninphotosensibilatoren für eine photodynamische therapie und verfahren zu ihrer herstellung und deren gebrauch | |
| WO2001071022A3 (en) | Lpa receptor agonists and antagonists and methods of use | |
| AP1424A (en) | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens. | |
| MXPA05013711A (es) | Derivados 3-sustituidos de 5,6-diaril-pirazin-2-carboxi-amida y -2-sulfonamida, como moduladores de cb1. | |
| BG103548A (en) | Vitronectine receptor antagonists | |
| EP0786995A4 (de) | ||
| DE69823222D1 (de) | Dihydronaphthalinderivate und verfahren zur herstellung derselben | |
| MY133390A (en) | Azabicyclic 5ht1 receptor ligands | |
| MY120976A (en) | 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines | |
| BG106930A (en) | Substituted phenyl-piperazine derivatives, their preparation and use | |
| GB9817573D0 (en) | Pharmaceutical compositions | |
| AUPR118000A0 (en) | Therapeutic molecules and methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1102753 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |